Syros Pharmaceuticals (NASDAQ:SYRS) Given a $10.00 Price Target at HC Wainwright

HC Wainwright set a $10.00 price objective on Syros Pharmaceuticals (NASDAQ:SYRS) in a research note issued to investors on Friday, TipRanks reports. The brokerage currently has a hold rating on the stock.

A number of other analysts have also commented on the company. Piper Jaffray Companies decreased their target price on Syros Pharmaceuticals from $24.00 to $18.00 in a research report on Thursday. JMP Securities decreased their target price on Syros Pharmaceuticals from $18.00 to $16.00 and set a market outperform rating for the company in a research report on Friday. ValuEngine raised Syros Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday. Zacks Investment Research raised Syros Pharmaceuticals from a sell rating to a hold rating in a research report on Saturday, September 28th. Finally, BidaskClub raised Syros Pharmaceuticals from a hold rating to a buy rating in a research report on Friday. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $15.03.

Shares of Syros Pharmaceuticals stock opened at $6.74 on Friday. Syros Pharmaceuticals has a one year low of $5.17 and a one year high of $11.93. The firm has a market capitalization of $295.37 million, a price-to-earnings ratio of -3.53 and a beta of 1.61. The business has a 50-day simple moving average of $9.99 and a 200 day simple moving average of $8.23. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.11 and a quick ratio of 8.11.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Thursday, August 1st. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.06). Syros Pharmaceuticals had a negative net margin of 3,137.55% and a negative return on equity of 79.79%. The firm had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.42 million. On average, sell-side analysts expect that Syros Pharmaceuticals will post -1.94 EPS for the current year.

In other Syros Pharmaceuticals news, Director Richard A. Young sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 14.80% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of SYRS. Bank of Montreal Can increased its holdings in Syros Pharmaceuticals by 11,319.2% during the 2nd quarter. Bank of Montreal Can now owns 2,969 shares of the company’s stock worth $27,000 after purchasing an additional 2,943 shares in the last quarter. A.R.T. Advisors LLC bought a new stake in Syros Pharmaceuticals during the 2nd quarter worth approximately $119,000. Susquehanna International Group LLP bought a new stake in Syros Pharmaceuticals during the 2nd quarter worth approximately $133,000. Algert Global LLC bought a new stake in Syros Pharmaceuticals during the 2nd quarter worth approximately $166,000. Finally, Bank of New York Mellon Corp increased its holdings in Syros Pharmaceuticals by 27.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 105,908 shares of the company’s stock worth $981,000 after purchasing an additional 22,658 shares in the last quarter. 82.08% of the stock is owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

See Also: How are dividend achievers different from dividend aristocrats?

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit